On a DART-disclosed basis, revenue rose from KRW 131.9 billion in 2022 to KRW 141.4 billion in 2023 (up 7.2% year on year) and KRW 149.4 billion in 2024 (up 5.7%), then fell to KRW 143.1 billion in 2025 (down 4.2%). Among the years from 2022 to 2025, 2024 was the largest year for revenue.
Operating profit went from KRW 5.85 billion in 2022 to KRW 1.96 billion in 2023 (down 66.4%), recovered to KRW 6.71 billion in 2024 (up 241.8%), and then fell to KRW 3.16 billion in 2025 (down 52.9%).
The operating margin was 4.4% in 2022, 1.4% in 2023, 4.5% in 2024 and 2.2% in 2025, so the 2025 decline came with both lower sales and a thinner margin.
Net income attributable to controlling shareholders swung to a loss of KRW 1.15 billion in 2023 from a profit in 2022, returned to a profit of KRW 531 million in 2024, and reached KRW 1.65 billion in 2025 (up 211.2%).
Net income including non-controlling interests is a different figure and stood at KRW 2.33 billion in 2025. At the end of 2025, total equity was KRW 79.1 billion, of which KRW 74.1 billion belonged to controlling shareholders, and total liabilities were KRW 131.7 billion.
The debt ratio rose from 143.7% in 2022 to 183.3% in 2023, then eased to 169.6% in 2024 and 166.4% in 2025. Operating cash flow was KRW 8.19 billion in 2022, negative at -KRW 214 million in 2023, and then KRW 5.25 billion in 2024 and KRW 5.43 billion in 2025.
On a quarterly basis, revenue fell from KRW 36.7 billion in Q3 2025 to KRW 33.7 billion in Q4 2025 (down 8.3% quarter on quarter), then rose to KRW 37 billion in Q1 2026 and KRW 41.3 billion in Q2 2026 (up 11.5%).
Operating profit stayed low at KRW 1.05 billion, KRW 699 million and KRW 454 million across Q3 2025, Q4 2025 and Q1 2026, then jumped to KRW 3.33 billion in Q2 2026 (up 633.9%).
In Q3 2026, revenue was KRW 35.3 billion (down 14.5% quarter on quarter and down 3.9% year on year), and the company posted an operating loss of KRW 1.29 billion. Net income attributable to controlling shareholders alternated between profit and loss across the last five quarters.
The trailing four-quarter total from Q4 2025 through Q3 2026 was KRW 2.36 billion.
According to press coverage of the third quarter, gross profit fell from KRW 12.2 billion to KRW 10.6 billion while selling and administrative expenses rose from KRW 11.2 billion to KRW 11.9 billion, and weakness in the API and cosmetics and medical device segments offset gains in drug manufacturing.
Q4 2025 net income attributable to controlling shareholders (KRW 3.18 billion) was far above operating profit (KRW 699 million), which suggests non-operating items affected the quarterly net result.